MedTrace Logo

Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)

NCT01346488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2088

Last updated 2017-04-13

Study results available
· View outcomes & findings →

Summary

This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.

This study is designed to provide additional data on treatment effects of adalimumab during 48 weeks of treatment in patients with RA under conditions of routine rheumatology care. Course of work productivity and work ability, the course of health-related quality of life, and changes in functionality during 48 weeks treatment with adalimumab are to be documented.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Sarina Kurimoto, MD · AbbVie

Eligibility

Min Age
15 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2016-01-31
Completion
2016-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01346488 on ClinicalTrials.gov